ArticleJMIR human factors2025
Optimizing SloMo, a Digitally Supported Therapy Targeting Paranoia, for Implementation: Inclusive, Human-Centered Design Study.
Article in JMIR human factors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite the promise of digital therapeutics in providing scalable interventions for psychosis, translating them from clinical trials to routine care is challenging. SloMo is an evidence-based, digitally supported cognitive behavioral therapy for psychosis comprising a web-based therapy platform and mobile app. The therapy encourages individuals to slow down for a moment, to address fast-thinking habits fueling paranoia. SloMo has received a NICE Early Value Assessment recommendation for use in the National Health Service to address evidence gaps related to its use in the real world, and an implementation study is underway.
objectiveThis study aimed to optimize the SloMo software for implementation by addressing limitations of the first release, reducing technology complexity, and improving user experience, to increase equitable outcomes.
methodsAn inclusive, human-centered design methodology was used to optimize SloMo. The redesign sought to reduce the technology's complexity and improve the user experience for diverse patients and therapists. The Double Diamond framework structured the iterative redesign, integrating insights from patient and public involvement consultants, therapists, and a transdisciplinary co-design team. The Double Diamond process was facilitated through 24 transdisciplinary workshops. These were supported by the following methods: identifying implementation barriers through desk research of SloMo's evidence and qualitative interviews with experts by experience (n=2); redefining user needs; iteratively developing solutions through user testing sessions with service user consultants (n=32); and validating the minimum viable product through think-aloud testing sessions with therapist (n=10) and service user (n=11) consultants.
resultsUsers wanted a form of cognitive behavioral therapy for psychosis that was usable, trustworthy, enjoyable, personalized, normalizing, and memorable. The redesign, therefore, included a minimalist user interface, more diverse lived experience vignette content, enhanced agency over data, greater representation of protected characteristics and their intersectionality, and intuitive navigation. Feedback from a purposively sampled patient and therapist sample validated the redesign as it was associated with a strong user experience, particularly in relation to usability and usefulness.
conclusionsThe study produced a redesign of the SloMo software optimized for real-world use, whilst retaining fidelity to the therapeutic content of the previous version. Through an inclusive, human-centered approach, the optimized design of SloMo addresses barriers to adoption by reducing complexity and fostering accessibility. This study underscores the value of integrating lived experience involvement into digital therapeutics to support scalable, equitable, and sustainable mental health care solutions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.